Brief: Ryvu Therapeutics Says Galapagos Exercises Option To License Inflammatory Disease Drug Program

Ryvu Therapeutics SA

14/12/2021 07:15

Dec 14 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * SAYS BELGIUM-BASED GALAPAGOS EXERCISES ITS EXCLUSIVE
OPTION TO
LICENSE PROGRAM WITH THERAPEUTIC POTENTIAL IN INFLAMMATORY
DISEASES
    * SAYS DUE TO EXERCISING OPTION COMPANY WILL GET PAYMENT OF
EUR
1.3 MILLION FROM GALAPAGOS
    * SAYS COMPANY WILL ALSO BE INTITLED TO SUBSEQUENT PAYMENTS
FOR
REACHING MILESTONES AS WELL AS FUTURE SALES ROYALTIES
    * SAYS COMPANY IS RESPONSIBLE FOR EARLY STAGES OF DRUG
DEVELOPMENT
UNDER RESEARCH AND DEVELOPMENT COOPERATION WITH GALAPAGOS

Source text for Eikon:  ID:nEM4SfMxva 
Further company coverage:  RVU.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))